UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2018
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At November 5, 2018, 5,780,474,578 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2018 and October 1, 2017
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2018 and October 1, 2017
Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and October 1, 2017
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
54
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
55
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
115
Item 4.
Controls and Procedures
115
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
116
Item 1A.
Risk Factors
116
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
117
Item 3.
Defaults Upon Senior Securities
117
Item 4.
Mine Safety Disclosures
117
Item 5.
Other Information
117
Item 6.
Exhibits
118
Signature
119
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2017 Financial Report
Financial Report for the fiscal year ended December 31, 2017, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017
2017 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2017
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Allogene
Allogene Therapeutics, Inc.
AMPA
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
Anacor
Anacor Pharmaceuticals, Inc.
AOCI
Accumulated Other Comprehensive Income
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ASU
Accounting Standards Update
ATM-AVI
aztreonam-avibactam
Avillion
Avillion LLP
Bain Capital
Bain Capital Private Equity and Bain Capital Life Sciences
Biogen
Biogen Inc.
BMS
Bristol-Myers Squibb Company
BRCA
BReast CAncer susceptibility gene
CAR T
chimeric antigen receptor T cell
CDC
U.S. Centers for Disease Control and Prevention
Cellectis
Cellectis S.A.
Cerevel
Cerevel Therapeutics, LLC
CIAS
cognitive impairment associated with schizophrenia
Citibank
Citibank, N.A.
CML
chronic myelogenous leukemia
Developed Markets
U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand
EEA
European Economic Area
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development
HER2-
human epidermal growth factor receptor 2-negative
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
J&J
Johnson & Johnson
King
King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LDL
low density lipoprotein
LEP
Legacy Established Products
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCC
Merkel Cell Carcinoma
MCO
Managed Care Organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation LLC (formerly Medivation, Inc.)
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
NDA
new drug application
NovaQuest
NovaQuest Co-Investment Fund V, L.P.
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PARP
poly ADP ribose polymerase
PBM
Pharmacy Benefit Manager
Pharmacia
Pharmacia Corporation
PP&E
Property, plant & equipment
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018
RCC
renal cell carcinoma
R&D
research and development
RPI
RPI Finance Trust
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
Servier
Les Laboratoires Servier SAS
SFJ
SFJ Pharmaceuticals Group
Shire
Shire International GmbH
SI&A
Selling, informational and administrative
SIP
Sterile Injectable Pharmaceuticals
S&P
Standard and Poor s
StratCO
Strategy and Commercial Operations
Tax Cuts and Jobs Act or TCJA
Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
Teuto
Laborat rio Teuto Brasileiro S.A.
U.K.
United Kingdom
U.S.
United States
ViiV
ViiV Healthcare Limited
WRD
Worldwide Research and Development
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
September 30,
2018
October 1,
2017
September 30,
2018
October 1,
2017
Revenues
13,298
13,168
39,670
38,843
Costs and expenses:
Cost of sales(a)
2,694
2,844
8,173
7,972
Selling, informational and administrative expenses(a)
3,494
3,504
10,448
10,249
Research and development expenses(a)
2,008
1,865
5,549
5,367
Amortization of intangible assets
1,253
1,177
3,640
3,571
Restructuring charges and certain acquisition-related costs
85
114
172
267
Other (income)/deductions net
(414
79
(1,143
65
Income from continuing operations before provision for taxes on income
4,177
3,585
12,831
11,351
Provision for taxes on income
66
727
1,270
2,287
Income from continuing operations
4,111
2,858
11,562
9,064
Discontinued operations net of tax
11
10
Net income before allocation to noncontrolling interests
4,122
2,858
11,571
9,066
Less: Net income attributable to noncontrolling interests
18
25
32
Net income attributable to Pfizer Inc.
4,114
2,840
11,546
9,034
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.70
0.48
1.96
1.51
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.70
0.48
1.96
1.51
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.69
0.47
1.92
1.49
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.69
0.47
1.92
1.49
Weighted-average shares basic
5,875
5,951
5,899
5,972
Weighted-average shares diluted
5,986
6,041
5,998
6,057
Cash dividends paid per common share
0.34
0.32
1.02
0.96
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
September 30,
2018
October 1,
2017
September 30,
2018
October 1,
2017
Net income before allocation to noncontrolling interests
4,122
2,858
11,571
9,066
Foreign currency translation adjustments, net
(567
878
(507
1,352
Reclassification adjustments
(2
(3
(22
110
(569
875
(530
1,461
Unrealized holding gains/(losses) on derivative financial instruments, net
222
(50
236
(149
Reclassification adjustments for (gains)/losses included in net income(a)
(235
56
119
(393
(13
355
(542
Unrealized holding gains/(losses) on available-for-sale securities, net
149
384
(65
698
Reclassification adjustments for gains included in net income(a)
(36
(278
(67
(181
Reclassification adjustments for unrealized gains included in Retained earnings(b)
(462
112
106
(595
518
Benefit plans: actuarial gains/(losses), net
(103
114
(41
Reclassification adjustments related to amortization
60
140
183
448
Reclassification adjustments related to settlements, net
42
38
108
89
Other
49
(76
69
(111
158
(1
474
384
Benefit plans: prior service costs and other, net
(2
Reclassification adjustments related to amortization
(46
(46
(137
(138
Reclassification adjustments related to curtailments, net
(4
(3
(18
(14
Other
(50
(48
(154
(151
Other comprehensive income/(loss), before tax
(361
938
(449
1,669
Tax provision/(benefit) on other comprehensive income/(loss)
62
(80
667
(218
Other comprehensive income/(loss) before allocation to noncontrolling interests
(422
1,018
(1,116
1,888
Comprehensive income before allocation to noncontrolling interests
3,700
3,876
10,455
10,953
Less: Comprehensive income attributable to noncontrolling interests
19
48
Comprehensive income attributable to Pfizer Inc.
3,700
3,857
10,450
10,906
(a)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(b)
For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
September 30,
2018
December 31,
2017
(Unaudited)
Assets
Cash and cash equivalents
3,559
1,342
Short-term investments
13,680
18,650
Trade accounts receivable, less allowance for doubtful accounts: 2018 $567; 2017 $584
10,024
8,221
Inventories
8,184
7,578
Current tax assets
3,686
3,050
Other current assets
2,450
2,301
Total current assets
41,583
41,141
Long-term investments
6,444
7,015
Property, plant and equipment, less accumulated depreciation: 2018 $17,078; 2017 $16,172
14,036
13,865
Identifiable intangible assets, less accumulated amortization
45,306
48,741
Goodwill
55,614
55,952
Noncurrent deferred tax assets and other noncurrent tax assets
1,875
1,855
Other noncurrent assets
2,980
3,227
Total assets
167,838
171,797
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2018 $4,255; 2017 $3,546
7,385
9,953
Trade accounts payable
4,297
4,656
Dividends payable
1,963
2,029
Income taxes payable
2,781
477
Accrued compensation and related items
2,096
2,196
Other current liabilities
10,490
11,115
Total current liabilities
29,013
30,427
Long-term debt
33,652
33,538
Pension benefit obligations, net
4,886
5,926
Postretirement benefit obligations, net
1,455
1,504
Noncurrent deferred tax liabilities
5,512
3,900
Other taxes payable
15,289
18,697
Other noncurrent liabilities
6,367
6,149
Total liabilities
96,174
100,141
Commitments and Contingencies
Preferred stock
20
21
Common stock
466
464
Additional paid-in capital
85,828
84,278
Treasury stock
(96,574
(89,425
Retained earnings
91,995
85,291
Accumulated other comprehensive loss
(10,417
(9,321
Total Pfizer Inc. shareholders equity
71,319
71,308
Equity attributable to noncontrolling interests
346
348
Total equity
71,664
71,656
Total liabilities and equity
167,838
171,797
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Nine Months Ended
(MILLIONS OF DOLLARS)
September 30,
2018
October 1,
2017
Operating Activities
Net income before allocation to noncontrolling interests
11,571
9,066
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
4,743
4,695
Asset write-offs and impairments
88
326
Adjustments to loss on sale of HIS net assets
(1
52
TCJA impact(a)
(410
Deferred taxes from continuing operations
(974
241
Share-based compensation expense
682
595
Benefit plan contributions in excess of income 2018 and expense 2017
(1,000
(1,042
Other adjustments, net
(1,169
(604
Other changes in assets and liabilities, net of acquisitions and divestitures
(2,441
(3,616
Net cash provided by operating activities
11,089
9,713
Investing Activities
Purchases of property, plant and equipment
(1,357
(1,256
Purchases of short-term investments
(7,364
(6,469
Proceeds from redemptions/sales of short-term investments
12,752
5,778
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less
385
2,758
Purchases of long-term investments
(1,503
(2,526
Proceeds from redemptions/sales of long-term investments
2,174
2,403
Acquisitions of businesses, net of cash acquired
(1,000
Acquisitions of intangible assets
(47
(188
Other investing activities, net
248
519
Net cash provided by investing activities
5,289
19
Financing Activities
Proceeds from short-term borrowings
1,945
7,003
Principal payments on short-term borrowings
(4,239
(7,659
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
(973
566
Proceeds from issuance of long-term debt
4,974
5,273
Principal payments on long-term debt
(3,104
(4,474
Purchases of common stock
(7,168
(5,000
Cash dividends paid
(6,015
(5,750
Proceeds from exercise of stock options
1,099
656
Other financing activities, net
(553
(223
Net cash used in financing activities
(14,034
(9,607
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(116
67
Net increase in cash and cash equivalents and restricted cash and cash equivalents
2,227
193
Cash and cash equivalents and restricted cash and cash equivalents, beginning
1,431
2,666
Cash and cash equivalents and restricted cash and cash equivalents, end
3,658
2,858
Supplemental Cash Flow Information
Non-cash transactions:
Receipt of ICU Medical common stock(b)
428
Promissory note from ICU Medical(b)
75
Equity investment in Cerevel Therapeutics, Inc. in exchange for Pfizer s portfolio of clinical and preclinical neuroscience assets(b)
343
Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets(b)
92
Cash paid (received) during the period for:
Income taxes
1,666
1,424
Interest
968
1,101
Interest rate hedges
(104
(183
(a)
As a result of the enactment of the TCJA in December 2017, Pfizer s Provision for taxes on income for the nine months ended September 30, 2018 was favorably impacted by approximately $410 million, primarily related to certain tax initiatives associated with the TCJA, as well as favorable adjustments to the provisional estimates of the legislation. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations.
(b)
For additional information, see Note 2B. Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment: Divestitures.